OBJECTIVE: To investigate the association of cigarette smoking with susceptibility to systemic sclerosis (SSc) in a large, well-defined patient population. METHODS: We conducted a review of 1,379 patients with SSc enrolled in the Scleroderma Family Registry and DNA Repository and/or the Genetics versus Environment in Scleroderma Outcome Study cohort. Smoking history was obtained from chart review or via telephone interview. Patients with SSc were subsequently categorized as never smokers or ever smokers. Patients with SSc for whom smoking data were available were matched 2:1 by age, sex, ethnicity, and state of residence to control subjects, using the Behavioral Risk Factor Surveillance System. RESULTS: The majority of patients were white (74.2%), with Hispanics and blacks representing 11.3% and 9.7%, respectively. Most patients had limited cutaneous involvement (54%). For our comparative analyses, 621 patients were matched with control subjects. There was no significant difference in age, sex, ethnicity, and SSc subtype between matched versus unmatched patients. The majority of patients had never smoked (57%), while 43% of patients were classified as ever smokers. The patients with SSc did not differ from control subjects in terms of their smoking behavior (odds ratio [OR] 1.020, 95% confidence interval [95% CI] 0.839-1.240, P=0.842). Anti-topoisomerase I antibody-positive patients were more likely to be never smokers (OR 0.648, 95% CI 0.421-0.998, P=0.049), whereas no such association was observed with anticentromere and anti-RNA polymerase III antibodies. CONCLUSION: Unlike its role in rheumatoid arthritis, smoking does not confer a risk for development of SSc, although it may impact disease severity.
OBJECTIVE: To investigate the association of cigarette smoking with susceptibility to systemic sclerosis (SSc) in a large, well-defined patient population. METHODS: We conducted a review of 1,379 patients with SSc enrolled in the Scleroderma Family Registry and DNA Repository and/or the Genetics versus Environment in Scleroderma Outcome Study cohort. Smoking history was obtained from chart review or via telephone interview. Patients with SSc were subsequently categorized as never smokers or ever smokers. Patients with SSc for whom smoking data were available were matched 2:1 by age, sex, ethnicity, and state of residence to control subjects, using the Behavioral Risk Factor Surveillance System. RESULTS: The majority of patients were white (74.2%), with Hispanics and blacks representing 11.3% and 9.7%, respectively. Most patients had limited cutaneous involvement (54%). For our comparative analyses, 621 patients were matched with control subjects. There was no significant difference in age, sex, ethnicity, and SSc subtype between matched versus unmatched patients. The majority of patients had never smoked (57%), while 43% of patients were classified as ever smokers. The patients with SSc did not differ from control subjects in terms of their smoking behavior (odds ratio [OR] 1.020, 95% confidence interval [95% CI] 0.839-1.240, P=0.842). Anti-topoisomerase I antibody-positive patients were more likely to be never smokers (OR 0.648, 95% CI 0.421-0.998, P=0.049), whereas no such association was observed with anticentromere and anti-RNA polymerase III antibodies. CONCLUSION: Unlike its role in rheumatoid arthritis, smoking does not confer a risk for development of SSc, although it may impact disease severity.
Authors: E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim Journal: J Rheumatol Date: 1988-02 Impact factor: 4.666
Authors: S P Linn-Rasker; A H M van der Helm-van Mil; F A van Gaalen; M Kloppenburg; R R P de Vries; S le Cessie; F C Breedveld; R E M Toes; T W J Huizinga Journal: Ann Rheum Dis Date: 2005-07-13 Impact factor: 19.103
Authors: Merete Pedersen; Søren Jacobsen; Mette Klarlund; Bo V Pedersen; Allan Wiik; Jan Wohlfahrt; Morten Frisch Journal: Arthritis Res Ther Date: 2006 Impact factor: 5.156
Authors: Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee Journal: Chest Date: 2017-06-16 Impact factor: 9.410
Authors: Evelien De Decker; Marie Vanthuyne; Daniel Blockmans; Frederic Houssiau; Jan Lenaerts; Rene Westhovens; Benoit Nemery; Ellen De Langhe Journal: Clin Rheumatol Date: 2018-02-23 Impact factor: 2.980